More information/research is needed Great to see this evidence emerging
When evaluating compounded semaglutide or tirzepatide options, combining your genetic predisposition profile with current disease activity data and IBD-specific biomarkers (fecal calprotectin, CRP) can support a more informed conversation with your provider about which formulation, dose, and monitoring schedule aligns with your health goals
Red Fox Peptides provides comprehensive quality documentation meeting these standards for Canadian researchers
(2023, Peptides) is worth reading alongside Willard for a mechanistic comparison of tirzepatide and semaglutide that goes beyond the raw binding numbers to receptor residence times and signaling bias
Mild side effects may include pain at the injection site, nausea, or dizziness
They are not medications, nor are they intended to diagnose, treat, prevent, or cure any disease or medical condition